(VELA) Study of BLU-222 in Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
Advanced Solid Tumors|HR+ Breast Cancer|CCNE1 Amplification|HER2-negative Breast Cancer|Ovarian Cancer|Endometrial Cancer|Gastric Cancer|Esophageal Adenocarcinoma|Carcinosarcoma
DRUG: BLU-222|DRUG: Carboplatin|DRUG: Ribociclib|DRUG: Fulvestrant
[Phase 1] Determine the maximum tolerated dose (MTD) of BLU-222, Approximately 21 months|[Phase 1] Determine the recommended Phase 2 dose (RP2D) of BLU-222, Approximately 21 months|[Phase 1] Rate and severity of adverse events, Approximately 21 months|[Phase 2] Overall response rate (ORR), Approximately 43 months|[Phase 2] Rate and severity of adverse events, Approximately 43 months
[Phase 1] Overall response rate (ORR), Approximately 21 months|[Phase 1] Time of last quantifiable plasma drug concentration (Tlast), Approximately 21 months|[Phase 1] Area under the plasma concentration time curve from time 0 to 12 hours (AUC0-12), Approximately 21 months|[Phase 1] Area under the plasma concentration time curve from time 0 to 24 hours (AUC0-24), Approximately 21 months|[Phase 1] Trough concentration (Ctrough), Approximately 21 months|[Phase 1] Apparent volume of distribution (Vz/F), Approximately 21 months|[Phase 1] Terminal elimination half-life (tÂ½), Approximately 21 months|[Phase 1] Apparent oral clearance(CL/F), Approximately 21 months|[Phase 1] Accumulation ratio (R), Approximately 21 months|[Phase 1] To assess treatment-induced modulation of biomarkers, Approximately 21 months|[Phase 1 and Phase 2] Duration of Response (DOR), Approximately 43 months|[Phase 1 and Phase 2] Disease control rate (DCR), Approximately 43 months|[Phase 1 and Phase 2] Clinical benefit rate (CBR), Approximately 43 months|[Phase 1 and Phase 2] Progression free survival (PFS), Approximately 43 months|[Phase 1 and Phase 2] Change in CA-125 levels, Approximately 43 months|[Phase 1 and Phase 2] Maximum plasma drug concentration (Cmax), Approximately 43 months|[Phase 1 and Phase 2] Time to maximum plasma drug concentration (Tmax), Approximately 43 months|[Phase 1 and Phase 2] Last measurable concentration (Clast), Approximately 43 months|[Phase 1 and Phase 2] Area under the concentration-time curve from time 0 to the time of the last measured concentration AUC(0-last), Approximately 43 months|[Phase 2] Overall survival (OS), Approximately 43 months
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.